EMA rejection bodes well for Aegerion, says Deutsche Bank Deutsche Bank said the European Medicines Agency's rejection of the re-examination request for Mipomersen in Homozygous Familial Hypercholesterolemia bodes well for the approval of Aegerion's Lomitapide in Europe. The firm reiterates a Buy rating on Aegerion with a $41 price target.
Aegerion price target lowered to $46 from $66 at Leerink Leerink lowered its price target for Aegerion shares to $46 after its survey of 40 U.S. cardiologists implied a more bearish outlook for Juxtapid once PCSK9s emerge. The firm, however, believes new patient adds are well outpacing Juxtapid discontinuations in the near term. It keeps an Outperform rating on the stock.